Effect of Levosimendan on Ventricular Systolic and Diastolic Functions in Heart Failure Patients: A Meta-Analysis of

Yu-Xiang Long1, Di-Yu Cui, Xue Kuang

  • 1Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Insights

Levosimendan improves heart function in heart failure patients by enhancing both systolic and diastolic parameters in both ventricles. This meta-analysis confirms its positive effects on cardiac function, particularly evident in echocardiographic measurements.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Imaging

Background:

  • Levosimendan is a calcium sensitizer used for inotropic support in heart failure.
  • Echocardiography is crucial for assessing cardiac function, yet limited studies explore levosimendan's effects using this modality.

Purpose of the Study:

  • To conduct a meta-analysis of randomized controlled trials evaluating levosimendan's impact on cardiac function via echocardiography.
  • To systematically pool echocardiographic parameters to quantify levosimendan's effects on ventricular function in heart failure.

Main Methods:

  • A comprehensive literature search was performed across PubMed, Embase, and CENTRAL databases up to August 2020.
  • Included were 29 randomized controlled trials involving 574 heart failure patients, with data extracted on 14 echocardiographic parameters.
  • A random-effect model was used to pool effect estimates for various cardiac function indices.

Main Results:

  • Levosimendan reduced left ventricular diastolic dysfunction, indicated by decreased early/late transmitral flow velocity ratio and E/e'.
  • Right ventricular systolic function improved, shown by increased tricuspid annular plane systolic excursion and peak systolic velocity, alongside reduced systolic pulmonary artery pressure.
  • Right ventricular diastolic function showed improvements with decreased Aa and increased Ea and Ea/Aa ratios.

Conclusions:

  • Levosimendan demonstrates a significant amelioration of both diastolic and systolic functions in both left and right ventricles of heart failure patients.
  • The findings support levosimendan's role in improving overall cardiac performance in heart failure, as evidenced by comprehensive echocardiographic analysis.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
645
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
905
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
582
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
539
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
64
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
144